



Notified Body Confirmation Letter Reference: C695322

To whom it may concern,

Confirmation of the status of a formal application, written agreement, and appropriate surveillance in the framework of Regulation EU 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices

This letter confirms that, DNV Product Assurance AS, a Notified Body (NB) designated against Regulation (EU) 2017/745 (MDR) and identified by the number NB 2460 on NANDO, has received a formal application in accordance with Section 4.3, first subparagraph of Annex VII of MDR and has signed a written agreement in accordance with Section 4.3, second subparagraph of Annex VII of MDR with the following manufacturer:

Madhu Instruments Pvt. Ltd.

A-260, Okhla Industrial Area, Phase-1, New Delhi – 110 020, INDIA

SRN Number: IN-MF-000017447

The devices covered by the formal application and the written agreement mentioned above are identified in the Tables below. Table 1 identifies the devices for which an MDR application has been received, written agreement concluded and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive. Table 2 identifies the devices for which an MDR application has been received and a written agreement concluded, but the NB has not yet taken the responsibility for appropriate surveillance of the corresponding devices under the applicable Directive.

In the case of devices covered by certificates issued under Directive 93/42/EEC (MDD) that expired after 26 May 2021 and before 20 March 2023, without having been withdrawn, this letter also confirms that the manufacturer signed the written agreement under MDR by the date of MDD certificate expiry; or provided evidence that a competent authority of a Member State had granted a derogation or exemption from the applicable conformity assessment procedure in accordance with Article 59(1) of MDR or Article 97(1) of the MDR respectively, by the 20 Mar 2023 for the relevant devices.

The transition timelines that apply to the devices covered by this letter, subject to the manufacturer's continued compliance to the other conditions specified in Article 120.3c of MDR (as amended by (EU) 2023/607), are shown below:

- 26 May 2026 for Class III custom-made implantable devices

Place and date:
Høvik, 10.11.2025



For the issuing office:
DNV Product Assurance AS – Notified Body 2460
Veritasveien 1, 1363 Høvik, Norway

Menaka Singh
Management Representative

Lack of fulfilment of conditions as set out in the Certification Agreement may render this letter invalid.

NOTIFIED BODY 2460: DNV Product Assurance AS, Veritasveien 1, 1363 Høvik, Norway, Tel +47 67 57 88 00, www.dnv.com